Navigation Links
The host makes all the difference
Date:3/26/2009

"Where there are many scientific works dealing solely with the flu virus, we have investigated how the host reacts to an infection," says Klaus Schughart, head of the Experimental Mouse Genetics research group. In infection experiments the researchers have now discovered that an excessive immune response is responsible for the fatal outcome of the disease in mice. This overreaction has genetic roots. The findings have now been published in the scientific magazine PLoS One.

For their investigations the researchers injected seven different inbred mouse strains with the same quantity of type Influenza A flu viruses. All of the animals within one mouse strain are genetically identical, like identical twins. However, one strain differs from another just like different individuals in the human population. To their surprise, the researchers were able to identify strong differences in the progression of the influenza between the seven strains. In five of the strains the illness was mild: the animals lost weight, recovering completely after seven to eight days. However, in two of the mouse strains the animals lost weight rapidly and died after just a few days.

The researchers looked for reasons for these differences: they investigated how the immune system of the animals responds to the virus. "The mice die from their own immune defences, which are actually supposed to protect them against the virus. The immune system produces too many messengers, which have a strong activating effect on the immune cells. These cells then kill tissue cells in the lungs that are infected with the virus," says Schughart. At the same time, these overactive cells also destroy healthy lung tissue. In mice that died the researchers also found one hundred times more viruses than in animals that survived. "It appears that the animals have specific receptors on their cells that make them more receptive to a severe viral infection." Flu infections in humans could take a
'/>"/>

Contact: Dr. Bastian Dornbach
bastian.dornbach@helmholtz-hzi.de
49-053-161-811-407
Helmholtz Association of German Research Centres
Source:Eurekalert

Page: 1 2

Related biology news :

1. The egg makes sure that sperm dont get too old
2. Tobacco makes medicine
3. Liking sweets makes sense for kids
4. Oh baby, interventional radiology makes childbirth safer
5. Red wine vs. white? It makes no difference when it comes to breast-cancer risk
6. Mount Sinai Hospital researcher makes stem cell breakthrough
7. Peptides-on-demand: McGill researchers radical new green chemistry makes the impossible possible
8. Rett Syndrome Research Trust advisor makes significant discovery
9. Tree lizard’s quick release escape system makes jumpers turn somersaults
10. Biophysical Reviews makes debut in 2009
11. Our unconscious brain makes the best decisions possible
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, a ... Internet of Things (IoT), today announced the appointment of ... operating officer. Previously a strategic advisor to the firm, ... operations. Mr. Traynor is based out of the C-Labs ... reports to Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... on mice, researchers found that a medication often used ... loss and helped tumors grow in bone. So the ... Louis are recommending increased awareness of bone health during ... growth factor commonly used to help cancer patients recover ...
... most important genes associated with a risk of developing type-2 ... study. , The research, published online in Nature, is the ... mapped in such detail. It should enable scientists to develop ... developing diabetes mellitus type 2, commonly known as type-2 diabetes. ...
... (CcO) is the ultimate enzyme responsible for all aerobic ... also a crucial component of the cellular machinery that ... you might expect that scientists would have a clear ... to James P. Collman, professor emeritus of chemistry at ...
Cached Biology News:Researchers urge monitoring of bone health during chemotherapy 2Researchers urge monitoring of bone health during chemotherapy 3Breakthrough in understanding type-2 diabetes as key genes identified 2Researchers create artificial enzyme that mimics the body's internal engine 2Researchers create artificial enzyme that mimics the body's internal engine 3
(Date:12/17/2014)... 17, 2014 This report is ... Tubing industry. For an overview analysis, the report ... industry chain structure, industry overview, policy analysis, and ... industry has witnessed rapid development with key ... acquisitions. This report mentions quartz tubing upstream raw ...
(Date:12/17/2014)... Diego, CA (PRWEB) December 17, 2014 ... and activation agency and member of the Huntsworth Health ... Gonzales to its executive team. In her role, Gonzales ... , “We are incredibly honored to welcome a ... Agency Chief and CEO, Gaëtan Fraikin. “She is a ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that the ... PVM technology , is now available. The new ... continuously captures high-resolution images under a wide range ... a report pairing the most relevant images to ... compelling blend of high resolution images and trend ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... today that,it received notice from Israel,s Chief Scientist,s Office ... D-Pharm,s R&D programs with a,total grant of up to ... PhD, CEO and President of D-Pharm, said "We are ... its firm support over the years,from the time of ...
... Researchers at The University of Manchester have used graphene ... and glimpse the foundations of the universe. , The ... by Professor Andre Geim, have found that the worlds ... which allows the direct determination of the fine structure ...
... includes refocusing of operations and workforce reduction, ... KERX ) today announced that it is ... burn rate and re-focus its,development efforts. The plan, ... Company,s pivotal SUN-MICRO Phase 3 clinical trial of ...
Cached Biology Technology:D-Pharm Secures Funding From Israel's Chief Scientist's Office 2Graphene gazing gives glimpse of foundations of universe 2Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 2Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 3Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 4
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: